HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jiangsu Hengrui Medicine Co. Ltd.

www.hrs.com.cn

Latest From Jiangsu Hengrui Medicine Co. Ltd.

Trade, IP And Oncology Deals: What You Need To Know About China And JPM20

China was a focus of discussions at the 2020 J.P. Morgan Healthcare Conference, as a Phase One trade agreement was signed to end a 17-month dispute with the US. Patent linkage and IP protection enforcement are also being closely watched, while Chinese firms including BeiGene continue to make strides in oncology deal-making.

China Deals

10 Commercial Trends To Watch In China in 2020

2019 will be remembered as a banner year for international drug makers as many grew at phenomenal rates in China, despite expansion of the “4+7” centralized procurement scheme and steep price cuts in exchange for reimbursement. As the government continues to emphasize affordability for cancer drugs and major anti-infectives, competition is heating up quickly and immune-oncology alone has seen six PD-1s elbowing each other for market share.

China Commercial

BeiGene's Brukinsa Fails In Head-To-Head But Hope Remains For Rare Indication

Days after bagging a US approval for its first global new drug, BeiGene was dealt a blow as its BTK inhibitor Brukinsa showed no significant superiority over class leader Imbruvica in Waldenström's macroglobulinemia, although the Chinese company remains hopeful for a possible approval.

Clinical Trials Blood & Coagulation Disorders

China Regulatory Roundup: AZ Gains PD-L1 Green Light Ahead Of Roche

Oncology continues to dominate new drug approvals in China as AstraZeneca gains the first clearance for a PD-L1 drug ahead of Roche. But there are as many as seven others in the class coming along, including from domestic firms Hengrui and CStone.

China Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Jiangsu Hengrui Medicine Co. Ltd.
  • Senior Management
  • Piaoyang Sun, Chmn.
    Lianshan Zhang, PhD, Pres., Global R&D
  • Contact Info
  • Jiangsu Hengrui Medicine Co. Ltd.
    Phone: 800 828 3900
    Lianyung Eco & Tech Development Zone
    7 Kunlunshan Rd
    , 222000
    China
UsernamePublicRestriction

Register